Previous studies have reported associations of IFITM3 SNP rs12252 with severe influenza, but evidence of association and the mechanism by which risk is conferred remain controversial. We prioritized SNPs in IFITM3 on the basis of putative biological function and identified rs34481144 in the 5′ UTR. We found evidence of a new association of rs34481144 with severe influenza in three influenza-infected cohorts characterized by different levels of influenza illness severity. We determined a role for rs34481144 as an expression quantitative trait locus (eQTL) for IFITM3, with the risk allele associated with lower mRNA expression. The risk allele was found to have decreased IRF3 binding and increased CTCF binding in promoter-binding assays, and risk allele carriage diminished transcriptional correlations among IFITM3-neighboring genes, indicative of CTCF boundary activity. Furthermore, the risk allele disrupts a CpG site that undergoes differential methylation in CD8 + T cell subsets. Carriers of the risk allele had reduced numbers of CD8 + T cells in their airways during natural influenza infection, consistent with IFITM3 promoting accumulation of CD8 + T cells in airways and indicating that a critical function for IFITM3 may be to promote immune cell persistence at mucosal sites.Our study identifies a new regulator of IFITM3 expression that associates with CD8 + T cell levels in the airways and a spectrum of clinical outcomes.
Influenza A virus (IAV) infections can cause major morbidity and mortality in human populations 1 , especially with the emergence of novel pandemic strains. In the 2009 H1N1 pandemic, although infection was considered to be generally mild, a number of pregnant women and otherwise fit young adults were severely afflicted. Having a screening marker that could be used to identify patients at high risk of severe illness would thus be of immense benefit for prioritizing treatment.
The antiviral protein IFITM3 inhibits viral entry into the host cell cytoplasm 2, 3 . IFITM3 also promotes the survival of mouse lungresident CD8 + T cells after IAV challenge, which may help clear the infection 4 . Given the importance of IFITM3 in animal studies and in vitro models 5, 6 , several groups have investigated polymorphisms in the IFITM3 gene for association with disease outcome. The C/C genotype at rs12252 in IFITM3 was linked to severe illness in adults during the 2009 IAV pandemic [7] [8] [9] , but the mechanism for the C risk allele remains unresolved. Correlation of the rs12252[C] allele with influenza severity has been validated in two cohorts of Han Chinese, where the majority of individuals carry at least one C allele 7, 10 , but not in cohorts of European ancestry [11] [12] [13] , suggesting that the effects of this allele may vary across ancestral populations. Although its role in human disease may be ambiguous, IFITM3 remains a strong candidate for a protein influencing influenza severity based on the increased susceptibility of IFITM3-deficient mice to influenza disease and the characterized activity of IFITM3 as a viral restriction factor.
In this study, we sought to define the biological mechanism underlying a genetic risk factor for severe clinical outcomes in influenzainfected patients who were previously healthy. We report a previously unknown association of single-nucleotide polymorphism (SNP) rs34481144 with severe influenza illness across three populations with varying degrees of disease severity, highlighting the broad public health potential of this SNP as a screening marker. We also define the mechanism by which rs34481144 influences regulation of IFITM3, the levels of which correlate with CD8 + T cell numbers at the site of infection.
RESULTS

A SNP in the IFITM3 promoter is associated with severity of influenza infection in three human cohorts
Several lines of evidence have suggested a role for IFITM3 in restricting influenza infection, including a previously reported association with SNP rs12252. However, the evidence of association for rs12252 is cohorts yielded an OR of 2.6 for the A allele with severe outcomes (P = 0.00024). Notably, all individuals included in the association analyses of the three cohorts were infected with influenza virus.
The influenza risk-associated SNP rs34481144 modulates expression of IFITM3 Given that rs34481144 resides within the promoter of IFITM3, we next sought to test whether it modulates transcription of IFITM3 in cohorts and cell types of interest, as it was found to be an eQTL in blood in the GTEx portal 17 . The region of the promoter surrounding rs34481144 is characterized by a DNase I-hypersensitive region, H3K4me3 and H3K27ac peaks, and multiple transcription factor binding sites (Fig. 1a) . To determine whether rs34481144 was associated with expression of IFITM3 in our FLU09 cohort, we performed an eQTL analysis using peripheral blood mononuclear cell (PBMC) expression data from 45 influenza-positive individuals. This analysis indicated that genotype at rs34481144 was associated with expression of IFITM3 (Fig. 2a) . Carriage of a single risk allele (A) was significantly associated with lower levels of IFITM3 expression (P = 0.008). Only one individual with RNA-seq data available was homozygous for the A allele, and the IFITM3 expression for this individual fell outside the 99% confidence interval of expression for the G/G genotype.
We next examined the eQTL status of rs34481144 in a population of healthy donors recruited at the Broad Institute for the Phenogenetic Project and ImmVar Consortium 18 (Fig. 2b) . Monocyte-derived dendritic cells from 200 subjects were stimulated with lipopolysaccharide (LPS) or interferon (IFN)-β or infected with influenza for 6 h. In all unstimulated and stimulated cells, there was significantly reduced expression of IFITM3 in subjects carrying the A risk allele (unstimulated, P = 4 × 10 −7 (Fig. 2b) ; LPS, P = 2 × 10 −12 ; IFN-β, P = 4.5 × 10 −19 ; influenza, P = 3.5 × 10 −16 ( Supplementary  Fig. 2a)) . We also performed an eQTL analysis using IFITM3 levels and rs12252 genotype, but detected no association of rs12252 genotype with IFITM3 expression except in IFN-β-stimulated cells, where there was a modest association between the risk C/C genotype at rs12252 and higher levels of IFITM3 (Supplementary Fig. 2b) . Finally, the eQTL status of rs34481144 was validated in the PICFlu study of critically ill children, where it was again shown that the risk genotype was associated with lower IFITM3 expression (P = 0.0003; Fig. 2c) . Collectively, data from three independent cohorts provide evidence that the risk allele at rs34481144 is associated with lower expression of IFITM3, suggesting a potential mechanism for the observed higher risk of severe influenza illness in individuals carrying this allele 5, 19 .
rs34481144 genotype determines IFITM3 promoter activity Having demonstrated that rs34481144 resides within an IFITM3 transcriptional regulatory region (Fig. 1a) , we proceeded to determine whether rs34481144 could directly alter IFITM3 promoter activity. Two luciferase reporter constructs were created in which expression was driven by the IFITM3 core promoter 20 (Figs. 1b and 2d) , one with the A allele, referred to as the risk promoter, and the other with the G allele, referred to as the protective promoter, and then transfected into the Jurkat and HEK293T cell lines. In Jurkat cells, both unstimulated (P = 0.02; Fig. 2e ) and concanavalin A (ConA)-stimulated (P < 0.0001; Supplementary Fig. 3a ) cells exhibited higher promoter activity when the G allele was present in the promoter construct. In HEK293T cells stimulated with polyinosinic:polycytidylic acid (poly(I:C)) or IFN-α or infected with influenza virus, the activity of the protective promoter was consistently higher than that of the risk promoter, at both 4 h disputed across cohorts and a mechanism is lacking for how this SNP confers risk. Thus, to identify other polymorphisms in IFITM3 that might contribute to influenza disease risk, we evaluated IFITM3 and its core promoter (Fig. 1a) . After SNP prioritization (described in detail in Supplementary Fig. 1 and the Online Methods), we found that rs34481144 satisfied our criteria. Population allele frequencies from the 1000 Genomes Project 14 for rs12252 and rs34481144 are listed in Supplementary Table 1 , and linkage disequilibrium (LD) between these two SNPs in these populations is included in Supplementary Table 2 . We genotyped rs34481144 in influenza-positive individuals from the FLU09 cohort from Memphis, Tennessee 12 ( Table 1) . The FLU09 cohort was a longitudinal study of naturally acquired influenza infection in which illness severity for patients was defined using clinical and symptom data collected throughout infection (Fig. 1b) . When we tested rs34481144, we found evidence of association of the A allele with the total symptom score in FLU09 patients (P = 0.037; odds ratio (OR) = 4.131; Fig. 1c ) and observed association in a similar direction with lower respiratory symptoms (P = 0.082; OR = 6.89). Haplotype analysis established that rs34481144 and rs12252 are not in high LD (r 2 = 0.031, D′ = 1). LD data for rs12252 and rs34481144 demonstrated that the C/C genotype at rs12252 (risk) was always inherited with the G/G genotype at rs34481144 (protective) in the FLU09 study, but the G/G genotype at rs34481144 was also coinherited with other rs12252 genotypes (C/T and T/T), indicating that the risk alleles for these SNPs are inherited on opposite haplotypes. Notably, the risk allele of rs34481144 was always inherited with the protective allele of rs12252 in the FLU09 cohort, suggesting that these SNPs provide non-overlapping indications of risk.
We assessed the association of rs34481144 with clinical metrics in individuals from two additional influenza cohorts (Fig. 1b and Table 1 ) at opposite ends of the influenza severity spectrum 15 . The Genentech Challenge Study, an influenza challenge study of healthy adults, assessed whether the rs34481144 risk allele is associated with increased influenza viral load. While data from studies using IFITM3-null mice and cells support the role of IFITM3 in restricting viral replication 8 , this challenge cohort presented a unique opportunity to examine the relationship between rs34481144 and early viral replication kinetics in human infection. Rapid replication was defined as viral load that was detectable by PCR or 50% tissue culture infections dose (TCID 50 ) assay in nasopharyngeal swabs less than 24 h after inoculation, whereas slow viral replication was defined as viral load that required 24 h or longer for detection. The A risk allele of rs34481144 was significantly associated with rapid viral replication in this challenge study (P = 0.01; OR = 3.6; Fig. 1c) , which may support the association of this allele with poor outcomes and directly relates carriage of the risk allele to the presumed function of IFITM3.
We sought further validation in a pediatric influenza cohort of critically ill children in the multicenter Pediatric Intensive Care Influenza (PICFlu) cohort 16 . In PICFlu patients positive for influenza infection with no predisposing conditions, the A allele at rs34481144 was associated with mortality (P = 0.047; OR = 2.0; Fig. 1c ). The majority of the patients with fatal infections (14/17) carried at least one A allele, suggesting that the A allele at rs34481144 increases risk of severe influenza illness. Because of the known differences in SNP frequency between Asian and European populations, we analyzed a subset of PICFlu patients who were of European descent. In this analysis, the association of rs34481144 with mortality was strengthened (P = 0.036; OR = 2.43), with all patients with fatal infections carrying at least one A allele. A meta-analysis pooling all 46 individuals with severe disease and 347 individuals with mild disease from these three (P < 0.0001; Supplementary Fig. 3b ) and 24 h (P < 0.0001; Fig. 2f ) after the start of treatment. The difference in promoter activity between the two genotypes was of equivalent or greater magnitude than the induction in activity resulting from any of the observed stimuli, indicating that genotype has a greater effect on expression than activation of innate immune signaling. However, the promoter in the reporter constructs is a minimal promoter and its activity may not represent the complete response of the full IFITM3 promoter. These data suggest that expression of IFITM3 is influenced by rs34481144 genotype, with individuals carrying the A allele having reduced IFITM3 promoter activity. (EMSAs) were performed by incubating nuclear extract from infected HEK293T cells or stimulated Jurkat cells with biotinylated 40-bp double-stranded DNA probes that included either the A or G allele at rs34481144. There was overall less protein binding to the probe containing the A allele than there was for the probe with the G allele in Jurkat ( Fig. 3a) and HEK293T ( Fig. 3b) cells, even at early time points of infection ( Supplementary Fig. 4a) . Thus, the change in promoter activity based on rs34481144 genotype is likely due to differential binding of proteins affecting the expression levels of IFITM3. Because the G allele was associated with higher IFITM3 expression, promoter activity, and protein binding to the promoter, we subsequently tested specific transcription factors involved in the innate immune response for binding to this SNP. In particular, we were interested in interferon-regulatory factor 3 (IRF3) because of its known roles in activating innate immune responses 21, 22 and controlling host responses to infection 23 . Western blotting-EMSAs (WEMSAs) were used to detect specific proteins that bound to the EMSA probes encompassing rs34481144. WEMSA data showed that IRF3 bound preferentially to the G allele in comparison to the A risk allele ( Fig. 3c and Supplementary Fig. 4b ), consistent with the idea that IRFs promote interferon-dependent antiviral immunity. STAT1, another critical transcriptional regulator of the interferon response, was found to bind equally to probes with the two genotypes ( Supplementary Fig. 4c ).
Our findings suggested that fewer positive regulators were binding the A risk allele, so we investigated whether inhibitory factors might preferentially bind the risk allele. Specifically, CTCF has many roles in regulating gene expression as an insulator and in its functions in chromatin architecture [24] [25] [26] . Data published in the Encyclopedia of DNA Elements (ENCODE) 27 from multiple cell lines including small airway epithelial cells (SAECs) indicated that CTCF binds to this region 28 , so we tested CTCF binding affinity for the IFITM3 promoter. CTCF bound more abundantly to the promoter containing the A allele than to the promoter with the G allele (Fig. 3d,e and Supplementary Fig. 4d ). Further evidence of the CTCF binding preference for each promoter was obtained using the predictive binding tool CTCFBSDB 2.0 (ref. 29) , which indicated that the 9-bp sequence including the risk allele (ACCCGACCA) was almost two times more likely to be a CTCF-binding site than the sequence containing the G allele (A allele position weight matrix (PWM) score = 76.1, G allele PWM score = 40.1; Fig. 1b) . These data illustrate a shift in binding based on genotype at rs34481144, with transcription factor occupancy tipped from a transcriptionally active profile with IRF3 binding of the protective promoter to an inactive profile in the presence of CTCF binding of the risk promoter.
Methylation status of rs34481144 differs between cell types CTCF promoter binding is regulated both by DNA sequence and DNA methylation, which reduces CTCF binding affinity 28 . In human isocitrate-dehydrogenase-mutant gliomas, hypermethylation compromises the binding site of CTCF, leading to increased and aberrant gene expression 30 . The protective G allele at rs34481144 creates a CpG site that the A risk allele disrupts; therefore, we hypothesized that, by abolishing a CpG site, the A allele removes the potential for DNA methylation and increases CTCF binding affinity in this promoter, as an additional mechanism that reduces IFITM3 expression levels.
We first sought to determine whether rs34481144 was methylated in cell populations of interest, including epithelial cells and monocytes. We examined the methylation status of the CpG site created by the G allele at rs34481144 in differentiated normal human bronchial epithelial (NHBE) cells from three donors with at least one G allele at IFITM3 expression levels measured by RNA-seq (log 2 (FPKM)) in PBMCs from 45 influenza-positive individuals in the FLU09 cohort plotted according to genotype at rs34481144. **P = 0.008, Welch's two-sample t test. In the box plots in a-c, the top and bottom of the box represent the 75th and 25th percentiles, the center line represents the median, and the whiskers extend to the data points that are no more than 1.5 times the interquartile range from the box. (b) IFITM3 expression levels (log 2 (IFITM3 counts) using Nanostring technology) in monocyte-derived dendritic cells from 534 healthy donors in the Phenogenetic Project and ImmVar Consortium plotted by genotype at rs34481144 and analyzed using linear regression modeling (P = 4 × 10 −7 ). (c) IFITM3 expression levels (log 2 -transformed signal from Affymetrix microarray) in whole blood from 62 critically ill children in the PICFlu cohort plotted by rs34481144 genotype and analyzed with one-way ANOVA (P = 0.0003). (d-f) Luciferase activity from two reporter constructs with the IFITM3 promoter. (d) Reporter constructs with different rs34481144 alleles included sequences from the core promoter of IFITM3 (Fig. 1b) subcloned 5′ of the firefly luciferase gene in the pGL4 plasmid. Luciferase plasmids were transfected into unstimulated Jurkat cells (e) and HEK293T cells that were left unstimulated or stimulated with poly(I:C) (1,000 U/ml), live influenza virus (1 multiplicity of infection (MOI)), or IFN-α (1,000 U/ml) for 24 h (f). Firefly luciferase activity was normalized to that of Renilla luciferase expressed from cotransfected plasmid. All luciferase experiments included at least three technical replicates and were repeated three times independently. In the box plots in e, the top and bottom of the box represent the 75th and 25th percentiles, the center line represents the median, and the whiskers represent minimum to maximum. Error bars in f, s.d. In HEK293T cells, two-way ANOVA was used to test whether genotype affected promoter activity across all treatments: ****P < 0.0001. For the analysis of unstimulated Jurkat cells only, a two-tailed, unpaired t test was performed to compare the genotypes (*P = 0.02).
rs34481144 after 24 h of influenza infection by locus-specific bisulfite sequencing. The CpG site in this subset of cells was fully demethylated (Fig. 4a and Supplementary Fig. 5a ). Monocytes were also sorted from six FLU09 patients, and we found that, regardless of genotype, the region was also demethylated in these cells ( Supplementary  Fig. 5b,c) . Therefore, methylation does not appear to be a mechanism through which occupancy of the IFITM3 promoter is altered in myeloid cells and infected lung epithelial cells.
In mice, lung-resident memory CD8 + T cells have increased Ifitm3 expression and this expression is required for survival after secondary influenza infection, demonstrating that IFITM3 in memory CD8 + T cells acts as an important antiviral resistance mechanism by promoting adaptive immunity 4 . On the basis of these findings, we hypothesized that memory T cells from FLU09 patients would have increased methylation at rs34481144 to block CTCF binding, allowing for increased expression of IFITM3. After sorting naive (T N ) and effector memory (T EM ) CD8 + T cells from FLU09 patients with the A/G or G/G genotype (Supplementary Fig. 5b ), we measured methylation at rs34481144 and found differences in methylation status among the cell subsets. In individuals with the G/G genotype, T EM cells had methylation at the CpG site of interest more often than T N cells (P = 0.03; CpG 2 in Fig. 4a; Supplementary  Fig. 5d-f ; complete methylation data for all cell types investigated are found in Supplementary Fig. 5 ). These data demonstrate that differential methylation at the rs34481144 locus is correlated with human effector and memory CD8 + T cell differentiation states.
To investigate the effect of DNA methylation at this locus on CTCF binding, we performed a WEMSA experiment assessing the ability of purified CTCF to bind to methylated versus unmethylated probe. CTCF binding affinity was greatest for the unmethylated A-allelecontaining probe, whereas methylation of this probe (in which there are two other CpG sites within the probe sequence) partially reduced binding; the unmethylated G-allele-containing probe had less binding, with the least amount of binding seen for the methylated version of the G-allele-containing probe (Fig. 4b) .
Although we had shown that rs34481144 is an eQTL for IFITM3 transcripts in total PBMCs (Fig. 2) , the observation that rs34481144 is differentially methylated in CD8 + T cells led us to measure protein levels of IFITM3 in this cell type. Consistent with the importance of rs34481144 genotype for IFITM3 expression, we found lower levels of IFITM3 protein in CD8 + T cells from individuals with the risk A/A genotype than in those with the protective G/G genotype; individuals with the A/G genotype had intermediate IFITM3 protein levels ( Fig. 4c and Supplementary Fig. 6 ). Interestingly, both A549 and HEK293T cells also have the A/A genotype and had similarly low levels of endogenous IFITM3 as PBMCs from individuals with the A/A genotype (Supplementary Fig. 7) .
Because of our finding that CD8 + T cells have differential methylation at rs34481144, we next sought to determine whether rs34481144 genotype had an effect on the number or frequency of lymphocytes in nasal washes from FLU09 patients. There were significantly more CD8 + T cells in the nasal washes of influenza-infected individuals with the G/G genotype than there were in washes from those with the A/G genotype (P = 0.012; Fig. 4d) , and this correlation with genotype was also seen in the frequency of CD8 + T cells among all viable cells (P = 0.009; Fig. 4d ). This effect seems to be specific to CD8 + T cells, as the correlation did not track with CD4 + T cell number (P = 0.21) or frequency (P = 0.07; Supplementary Fig. 8a,b) . Notably, when we used linear regression to analyze the correlation between the frequency of CD8 + T cells and rs34481144 genotype, the correlation was significant (P = 0.04), even when adjusting for viral titer at day 0 (P < 0.04). We have observed that, after resolution of infection and in uninfected individuals, CD8 + T cells are not present in the nasal wash, but CD8 + T cells in the nasal wash are tetramer specific at the peak of infection (data not shown). These data provide support for a mechanism whereby methylation at rs34481144 reduces CTCF binding, leading to elevated IFITM3 levels and resulting in enhanced accumulation of effector CD8 + T cells in the airways.
Transcriptional regulation of IFITM3-neighboring genes is altered by rs34481144 genotype CTCF binding is known to alter chromatin topology, changing the proximity of promoters and enhancers and leading to correlated changes in the transcriptional levels of genes within a broad locus, or domain 31, 32 . Domain boundaries can be deduced by changes in gene expression correlation within a domain region; correlation is reduced or lost when the domain is interrupted 30, 33 . To determine whether expression correlation for gene pairs changed with rs34481144 genotype, we analyzed the expression levels of genes <300 kb from rs34481144, to encompass any potential domain and surrounding region, using RNA-seq data from the FLU09 cohort. We found correlations between gene expression levels in individuals with the G/G genotype (Fig. 4e) that were absent in individuals with the A/G genotype (Fig. 4f) , indicative of a change in a domain boundary likely due to the effects of differential occupancy by CTCF based on rs34481144 genotype, as has been reported for other SNPs 34 . Expression correlation with IFITM3 levels was subsequently tested for these genes individually, and we found the same domain region differences ( Supplementary Fig. 9 and Supplementary Table 3 RIC8A  SIRT3  PSMD13  NLRP6  ATHL1  IFITM2  IFITM1  IFITM3  B4GALNT4   SIGIRR  ANO9  RNH1  HRAS  LRRC56  C11orf35  RASSF7  MIR210HG   PHRF1   SCGB1C1  BET1L  RIC8A  SIRT3  PSMD13  NLRP6  ATHL1  IFITM2  IFITM1  IFITM3  B4GALNT4  SIGIRR  ANO9  RNH1  HRAS  LRRC56  C11orf35  RASSF7  MIR210HG PHRF1 RIC8A  SIRT3  PSMD13  NLRP6  ATHL1  IFITM2  IFITM1  IFITM3  B4GALNT4   SIGIRR  ANO9  RNH1  HRAS  LRRC56  C11orf35  RASSF7  MIR210HG   PHRF1   SCGB1C1  BET1L  RIC8A  SIRT3  PSMD13  NLRP6  ATHL1  IFITM2  IFITM1  IFITM3  B4GALNT4  SIGIRR  ANO9  RNH1  HRAS  LRRC56  C11orf35  RASSF7  MIR210HG Welch's two-sample t tests were used to analyze differences between the genotypes (number, P = 0.012; frequency, P = 0.0096). The top and bottom of the boxes represent the 75th and 25th percentiles, the center line represents the median, and the whiskers extend to the data points that are no more than 1.5 times the interquartile range from the box. (e,f) Spearman correlation analysis using Corrplot for expression of genes within 180 kb of rs34481144 (chr. 11: 237,460-405,459) in patients with the G/G genotype (e) and the A/G genotype (f). Only significant correlations (after false discovery rate (FDR) adjustment) are shown, ordered by genomic position. Blue, positive correlation; red, negative correlation. See Supplementary Table 3 for results (R and P values) from individual correlation analysis with IFITM3.
The expression levels of all IFITM family members appeared to be strongly correlated with each other regardless of genotype. We found significant expression correlations for IFITM1 and IFITM2 with IFITM3 (Supplementary Fig. 10a ) as well as correlations at the protein level for IFITM1 and IFITM3 (Supplementary Fig. 10b ), suggesting that regulatory processes that are identified with a single IFITM gene could be compounded by influencing the expression (either up or down) of all IFITM genes.
DISCUSSION
Here we report that rs34481144 is associated with IFITM3 gene expression, methylation status of the corresponding CpG site in specific cell subsets, IFITM3 protein levels directly assessed in CD8 + T cells, and the transcriptional landscape of the broader region including immunerelated genes. We also identify a new association of rs34481144 with severe influenza illness in human cohorts. We further show an association with CD8 + T cell levels in the airways of influenza-infected patients. The consistency of our findings across independent cohorts of varying disease severity and the correlation with CD8 + T cell number in the airways suggest that screening for rs34481144 could be useful for identifying individuals at particular risk for severe outcomes.
These results suggest that rs34481144 may have clinical implications for severe illness outcome in individuals such as those enrolled in the PICFlu cohort, who were selected on the basis of the absence of known risk factors. Such individuals are unlikely to be categorized as 'at higher risk' in the event of a pandemic. A major limitation of the genetic analysis in this study is the size of the cohorts used for association of rs34481144 with severe influenza illness. To use the most applicable population for our question, we required that all individuals included in the association analyses be infected with influenza virus, with case and control status determined by the severity of illness. We argue that this is a more informative methodology for identifying underlying genetic factors contributing to risk of severe illness than comparing influenza-infected cases to healthy donor controls whose history of response to infection is unknown. Cohorts with extensive influenza viral and clinical data are costly and difficult to accrue, which limited us to small numbers. We have comprehensive phenotyping of all subjects in these three cohorts, which we suggest provides further confidence for the association. Moreover, we suggest that our functional assays strengthen the argument for a clinical association by detailing how this SNP directly influences the expression and promoter activity of IFITM3, influences binding of transcription factors partially through methylation status, and is correlated with CD8 + T cell levels in the airways of influenza-infected patients. However, validation of this association in a large, well-powered cohort of the same case-control structure is a goal for our future studies.
Use of the Genentech Challenge Study population allowed us to investigate the effect of the SNP on viral kinetics, a known innate immune mechanism by which IFITM3 can abate influenza replication. Intriguingly, while IFITM3 is conventionally thought to have a critical role only in innate immune restriction of viral replication, our results suggest that this locus is specifically regulated in activated and memory CD8 + T cell subsets. Mouse models support a role for IFITM3 in protecting CD8 + T cells in the airways, and the phenotype of increased viral titer does not appear in knockout animals until after day 5 of infection, a time point associated with adaptive immune control 4, 8 . In most human cohorts, including our own, the antiinfluenza immune response is a secondary recall response for T cells, as individuals usually have been infected or vaccinated with influenza by the age of 2 years. Thus, modulators of innate immunity that can promote robust adaptive recall responses may be critically important in influencing the outcome of this infection.
Genotype at rs34481144 influences CTCF binding and was found to be correlated with expression in the broader locus surrounding IFITM3, which includes several genes known to be involved in host responses to viral infection. Because of differences in the allele frequencies of IFITM3 SNPs among ancestral populations, further study is necessary to investigate differences in the distribution of transcription factor binding in this region that affect regulation of the broader locus. Indeed, the minor allele of rs12252 is carried at much higher frequencies in Han Chinese and other populations of Asian descent than that for rs34481144, with the opposite observed in populations of European descent. It is possible that these two SNPs correlate with differentially organized chromatin domains. Additionally, given the known diverse effects of genes in this locus on immunological outcomes, we would expect other infections to be influenced by polymorphisms in this region. The minor allele of rs12252 has been associated with HIV progression in a Chinese cohort 35 . However, the truncation mutant predicted to result from rs12252 (ref. 8 ), which has not been observed in published studies, was able to restrict HIV replication 36 , so this association may indicate a role for other effects of this locus.
One gene in this locus whose expression showed a strong negative correlation with IFITM3 expression in individuals with the G/G genotype is B4GALNT4, which produces an acetylgalactosaminyltransferase that has a role in O-glycosylation and mucin production, an important process in the host response to viral infection 37 . Currently, there is no literature on the role that B4GALNT4 may have in host response to viral infection, but it is known that mice deficient in B4galnt3, a paralog of B4galnt4, display significantly reduced influenza virus replication during the early stages of infection 38 . This example illustrates that complex regulation of this locus may affect multiple host antiviral pathways, warranting additional study in response to multiple infections. This example also illustrates that evolutionary pressure to keep the risk allele of rs34481144 may be due to the effects of another gene or genes in the broader locus that are important in a non-influenza context.
Taken together, our results suggest that differential rs34481144 methylation in CD8 + T cells influences IFITM3 levels and may contribute to the accumulation of this important cell type at the site of influenza infection. As IFITM3 has been reported to have roles in epithelial cells 6 , endothelial cells 39 , and dendritic cells 40 , we will explore its regulation in these cells in future studies. The current analysis indicates that the innate immune factor IFITM3 may have a key role in regulating the cellular response and severity of influenza infection at least in part through its expression in CD8 + T cells.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
Study participants and design. The FLU09 cohort has been described previously 41 with additional recruitment for year 5 of the study. Briefly, the inclusion criteria required that participants meet the clinical case definition of influenza virus infection at the time of enrollment or be asymptomatic household contacts of a participant with confirmed influenza infection. Exclusion criteria included refusal to consent to nasal lavage, history (within 3 months of enrollment) of having received immunoglobulin or other blood products, and presence of a condition that would predispose the participant to unacceptable injury or render the participant unable to meet the requirements of the study. Inclusion and exclusion criteria were established before enrollment of the participants. This study was conducted in compliance with 45 CFR46 and the Declaration of Helsinki. The institutional review boards of St. Jude Children's Research Hospital and the University of Tennessee Health Science Center/Le Bonheur Children's Hospital approved the study. Written, informed consent was acquired from participants' parents or guardians and written assent from age-appropriate subjects was acquired at the time of enrollment. Index cases were asked to provide nasal swabs, nasal lavages, and blood on the day of enrollment (day 0) and days 3, 7, 10, and 28, whereas household contacts were asked to provide nasal swabs on days 0, 3, 7, and 14 and blood and nasal lavages on days 0 and 28. The population used for these analyses was predominantly African American (81.4%) with 18.6% Caucasian participants (n = 86). Metadata collected from this study included information on several symptoms that were ranked daily (self-reported) according to a visual analog scale. These symptoms included systemic (fever, fatigue, headache, body ache, chills, lethargy, and irritability), upper respiratory (sore throat, stuffy nose, earache, and sinus pressure), lower respiratory (cough, shortness of breath, and wheezing), and gastrointestinal (nausea, vomiting, and diarrhea) symptoms. FLU09 participants were stratified into patient groups with mild and severe illness by the total peak symptom score during infection, with those with severe illness having a total peak score greater than 600. Severe lower respiratory tract symptom status was defined as the presence of shortness of breath and wheezing.
In the Genentech Challenge Study, healthy volunteers from 18 to 45 years of age and seronegative in hemagglutination inhibition (HAI) assays toward A/Wisconsin/67/2005 (H3N2) IAV were enrolled and provided written, informed consent. The London, City and East Research Ethics Committee approved the study protocol. This trial (ClinicalTrials.gov identifier NCT01980966) was registered and conducted in full conformance with the ICH E6 guidelines for Good Clinical Practice, the EU Good Clinical Practice Directive (2005/28/EC), the Declaration of Helsinki, and applicable laws and regulations. While the study was an interventional cohort, we did not analyze or report any data from the intervention but only from the control period before application of the intervention. The patient population of this study was predominantly of European ancestry (94.9%), with a small percentage self-identified as Asian (1.7%) or African (3.4%). Enrolled volunteers received an intranasal inoculation of approximately 5.0-5.5 log 10 TCID 50 of influenza A/Wisconsin/67/2005 H3N2 (Baxter). In this study, we do not report the primary endpoint for this trial (an interventional study testing a specific agent) but rather the results of a secondary analysis of the control individuals in the study to test our hypothesis of genetic regulation of viral control. Forty-seven participants became positive for viral infection, as determined by detection of virus in nasopharyngeal swabs by qRT-PCR and/or TCID 50 , in the 7 d following inoculation; of these, 42 passed quality control for subsequent genetics analysis. Rapid replication was defined as detectable virus <24 h after inoculation, while slow viral replication was defined as virus requiring ≥24 h for nasopharyngeal swabs to be positive by PCR or TCID 50 assay.
The PICFlu study was a multicenter study of influenza critical illness in North American children admitted across 31 pediatric intensive care units (PICUs) 16 . Site institutional review boards approved the study. Informed consent was obtained from at least one parent for each participant. Exclusion criteria have been described previously in detail; briefly, children were excluded for certain preexisting lung disorders, immunocompromised status, mitochondrial disorders that could predispose to severe infection, certain genetic or neurological disorders, preexisting cardiac disease that could affect lung function, or influenza infection considered to be acquired nosocomially by hospital personnel. Inclusion and exclusion criteria were established before enrollment of the participants.
PICFlu investigators enrolled 316 influenza-positive children with confirmed influenza infection who presented to the PICU with critical illness (acute respiratory failure and/or vasopressors), 265 of whom had no predisposing conditions known to increase risk for such severe illness. The population was predominantly of European ancestry (73.2%) with 13.2% African Americans, 4.9% Asians, and 8.7% mixed or other. The most severe phenotype for influenza illness (mortality) was tested for association with rs34481144 genotype in this cohort. Of the 265 patients enrolled in the study, 17 died and 248 survived.
Prioritization and Sanger sequencing of IFITM3 SNPs. To prioritize SNPs for genotyping in the FLU09 cohort, we followed the scheme illustrated in Figure 1a . In brief, common SNPs (MAF > 1%) within the IFITM3 gene and core promoter 20 were tested for their status as eQTLs using the GTEx portal 17 . SNPs that were eQTLs for IFITM3 were then investigated for allele frequency differences between Asian (CHB) and European (CEU) populations using 1000 Genomes Project data 14 . This step was necessary to address the debate over rs12252 association in populations of European descent. Following this filter, we prioritized SNPs on the basis of regulatory potential using ENCODE data 27 in the UCSC Genome Browser. From this scheme, rs34481144 was determined to be the SNP with the highest priority for genotyping in FLU09. GTEx data determined that rs34481144 was an eQTL for IFITM3 (P = 2.6 × 10 −7 ) in blood, with the risk allele associated with lower IFITM3 expression.
All individuals from the three cohorts described above were genotyped by one of two methods. The first method, used for samples from both FLU09 and the Genentech Challenge Study, amplified a fragment of the IFITM3 gene on chromosome 11 from purified patient DNA by a touchdown PCR approach using previously published primers 7 (forward, 5′-GGAAACTGTTGAGAAACCGAA-3′; reverse, 5′-CATACGCACCTTCACGGAGT-3′), where the annealing temperature was reduced each cycle from 70 °C by 1 °C for 10 cycles and then kept at 60 °C for 25 additional cycles. The resulting 352-bp PCR fragment was purified using a QIAquick PCR Purification kit (Qiagen) and sequenced by Sanger sequencing using the following forward and reverse primers, respectively: 5′-ACAGCCACCTCGTGCTCCTC-3′ and 5′-GTTGAGAAACCGAAACTACTGGG-3′. SNP genotypes were determined by inspection of sequencing chromatogram files using Sequencher (Gene Codes Corp) and CLC Main Workbench 7.5 (CLC Bio). The second genotyping method used for samples from the PICFlu cohort has previously been published 13 . Genotype concordance was measured at 100% between the two genotyping methods used in this study.
Genotype data quality control and association analysis. Genotype data for rs34481144 were obtained using Sanger sequencing. Association analysis for the FLU09 cohort was performed using linear mixed models as implemented in the software GEMMA 42 . The relatedness matrix required by the method was estimated using genotype data for the samples from the Illumina HumanOmni25M array, which was only used for sample quality control purposes. SNP rs34481144 was not present on the array. The estimated genomic inflation factor (λ GC ) was 1.019. Haplotype analysis was conducted using PLINK to determine LD between the two genotyped SNPs rs12252 and rs34481144.
For the Genentech Challenge Study, only subjects with self-reported European ancestry (n = 42) were selected for association analysis. Association analysis was performed using the PLINK --logistic command using rapid viral replication as a binary phenotype that was regressed on additively coded genotype at rs34481144. For the PICFlu cohort, PLINK was used to analyze association of rs34481144 with the dichotomous phenotype of mortality (yes/no).
Meta-analysis was performed using METAL 43 . A fixed-effects model based on inverse variance weighting was used to combine summary statistics across the studies, and a test of the heterogeneity of effects was performed (P = 0.48). eQTL analysis. Expression levels of IFITM3 from RNA-seq data were compared by rs34481144 genotype. RNA-seq data were available for 45 influenza-infected individuals with genotype data. For RNA-seq, total RNA was extracted from PBMCs collected on the day of enrollment using the RNeasy kit (Qiagen). Total RNA was extracted from PBMCs from influenza-infected patients who had mild to severe clinical outcomes. Quality and quantity for the RNA samples were determined before their processing by RNA-seq RNA concentration for RNA samples was determined using a NanoDrop 8000 (Thermo Scientific), and RNA integrity was determined by Fragment Analyzer (Advanced Analytical Technologies). One microgram of total RNA was used as input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). Library size was confirmed using Fragment Analyzer (Advanced Analytical Technologies), and library concentration was determined by a qPCR-based method using the Library quantification kit (KAPA). The libraries were multiplexed and then sequenced on an Illumina HiSeq 2500 (Illumina) to generate 30 million single-end 50-bp reads. For each RNA-seq sample, fastq files were mapped to the hg19 genome using both BWA 44 and STAR 45 . Reads were counted with HTSEQ 46 , and log 2 (FPKM) values stabilized by the addition of 2 before transformation were generated using STATA/MP 12. These log 2 -transformed values were imported into Partek Genomics Suite 6.6 associated with clinical metadata and analyzed via PCA. The log 2 (FPKM) values for IFITM3 were compared among the three genotype groups. Only one individual from the RNA-seq data set had the A/A genotype; therefore, we were unable to run ANOVA to compare the three genotypes. A Welch two-sample t test was performed to compare IFITM3 expression levels between individuals with the A/G and G/G genotypes at rs34481144 using R in RStudio. The 95% and 99% confidence intervals for the mean IFITM3 expression levels in individuals with the G/G genotype were calculated using GraphPad Prism to determine where the expression level for the individual with the A/A genotype was in comparison to the range for individuals with the A/G and G/G genotypes.
Data from the Phenogenetic Project at the Broad were used to analyze IFITM3 expression based on genotype at rs34481144 and rs12252 in monocyte-derived dendritic cells as described previously 18 . Briefly, patient monocyte-derived dendritic cells were left unstimulated, stimulated with LPS or IFN-β, or infected with influenza, and transcriptome analysis was then conducted using Nanostring technologies. Linear regression of IFITM3 expression level was performed on additively coded (0, 1, or 2) genotype, and significance was assessed using the Wald test for genotype effect size.
Microarray data from PICFlu at Boston Children's Hospital were used to analyze association of IFITM3 expression with rs34481144 genotype. Blood was collected in PAXgene tubes (PreAnalytiX, Qiagen/BD) and managed according to the manufacturer's specifications. RNA was extracted from whole blood with PAXgene Blood RNA System kits (PreAnalytiX, Qiagen) using the manufacturer's protocol from the manual or the automated QIAcube protocol. RNA quality and concentration were determined using a NanoDrop ND1000 (Thermo Scientific). RNA integrity was assessed by Agilent 2100 Bioanalyzer using the RNA 6000 Nano Assay kit according to the manufacturer's instructions (Agilent Technologies). Sixty-three patient RNA samples were assayed on the HuGene-1_0-st-v1 Affymetrix microarray. CEL file data were quality controlled and RMA summarized 47 using Partek Genomics Suite 6.6. Statistical analysis was conducted using one-way ANOVA in GraphPad Prism to determine whether expression was associated with genotype. Variance between genotype groups was found to be similar by Bartlett's test.
All eQTL box plots were generated in R with the boxplot function using default plotting parameters. The top and bottom of each box represent the 75th and 25th percentiles (the upper and lower quartiles), and the center line represents the median. The whiskers extend to data points that are no more than 1.5 times the interquartile range from the box.
Luciferase assays. Differences in promoter activity due to genotype at rs34481144 were measured using a luciferase assay. A luciferase assay of the promoter activity of IFITM3 has been described previously 20 and was modified for our SNP of interest, rs34481144. Briefly, genomic DNA was extracted from HEK293T and Jurkat cells using Qiagen's DNA mini kit. The IFITM3 core promoter (chr. 11: 320,813-321,159) was amplified using the following primers: (F) 5′-TATACTGCAGCTAGCGAGCCCTGAACCGGGACAGTG-3′; (R) 5′-TATA CTGCACTCGAGTGGTGTCCAGCGAAGACCAGC3′. PCR product was validated using the primer sequences (F) 5′-GAGCCCTGAACCGGGACAGTG-3′ and (R) 5′-TGGTGTCCAGCGAAGACCAGC-3′. Site-directed mutagenesis was used to mutate rs34481144 in the PCR product from the A allele to the G allele before cloning into the plasmid using primers 5′-ACCATCCCAGTAA CCCGACCGCCGCTGGTCTTCGCTGGACA-3′ and 5′-TGTCCAGCGAA GACCAGCGGCGGTCGGGTTACTGGGATGGT-3′ with the QuikChange (Agilent Technologies) protocol according to the manufacturer's instructions. Two plasmids were constructed by independently inserting the two promoters (A and G alleles) between the NheI and XhoI sites of the pGL4 Basic vector (Promega) with the coding region for firefly luciferase. Colonies were selected using LB with ampicillin, and Sanger sequencing was used to validate the sequence of the resulting constructs. HEK293T and Jurkat cells were transfected with DNA for each reporter plasmid using TransIT Transfection Reagent (Mirius Bio). Briefly, cells were seeded into 96-well flat-bottom plates at 50,000 cells/well, and 0.15 µg of pGL4 (IFITM3prom-A or IFITM3prom-G) plasmid and 0.15 µg of pRL plasmid were added. All transfections were carried out in triplicate. Twenty-four hours after transfection, cells were washed with PBS and treated. HEK293T cells were treated with INF-α (1,000 U/ml) or infected with influenza (1 MOI A/Brisbane/59/07) for 4 and 24 h, and Jurkat cells were stimulated with ConA (2.5 µg/ml). Untreated controls were also included. Dual-luciferase activity was measured using the Dual-Luciferase Assay (Promega) on the GloMax platform. To determine whether genotype had an effect on luciferase activity across treatments, statistical analysis was performed using two-way ANOVA in Prism software (GraphPad). For analysis of unstimulated Jurkat cells only, a two-tailed unpaired t test was performed to assess the difference between genotypes (P = 0.02), and equal variance was found between groups. Two-way ANOVA was used to look at differences based on genotype across unstimulated and ConA-stimulated cells (P < 0.0001; Supplementary Fig. 3a ).
Electrophoretic mobility shift assays. Oligonucleotides were synthesized for the region surrounding the rs34481144 SNP in the promoter of IFITM3 to create 40-bp probes (IDT). The sequences for the probe with the A genotype were as follows: (F) 5′-AGTAACCCGACCACCGCTGGTCTTCGCTGGACA CCATGAA-3′ and (R) 5′-TTCATGGTGTCCAGCGAAGACCAGCGGTGG TCGGGTTACT-3′. The sequences for the probe with the G genotype were as follows: (F) 5′-AGTAACCCGACCGCCGCTGGTCTTCGCTGGACACCATG AA-3′ and (R) 5′-TTCATGGTGTCCAGCGAAGACCAGCGGCGGTCGGG TTACT-3′. Oligonucleotides were biotinylated at the 5′ end (IDT). Unlabeled probes were also ordered using the same sequences for specific competition of the labeled probes. The complementary oligonucleotides were annealed to produce double-stranded oligonucleotide probes. HEK293T and A549 cells were infected with 5 MOI A/Brisbane/59/07 for various time points from 30 min to 24 h for this experiment. Jurkat cells were stimulated with PMA (50 ng/ml) for 2-48 h. Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific). Binding reactions were performed with the LightShift Chemiluminescent kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, the binding reaction was prepared with 1× binding buffer (100 mM Tris, 500 nM KCl, 10 mM DTT; pH 7.5), 4% glycerol, 1 mM MgCl 2 , 5 mM EDTA, and 1 µg of poly(I:C), and 3 µl of nuclear extract was added before incubation with 20 fmol of each of the test probes (A or G genotype). For specific competitor binding reactions, a 300-fold molar excess of the unlabeled probe was added to the binding reaction mixture before addition of the test probe. Reactions were loaded onto a Novex 6% DNA Retardation Gels TBE ready gel (Life Technologies) and run at 250 V for 20 min on ice; they were then transferred on ice to nylon membrane (380 mA for 45 min). DNA was cross-linked to the membrane at 120 mJ/cm 2 using the Stratalinker UV Crosslinker (Stratagene) before continuing with the LightShift Chemiluminescent kit to detect the biotinylated probes.
For WEMSAs 48 , probes were incubated with nuclear extract, purified fulllength recombinant CTCF protein (100 ng; Abnova), or purified full-length recombinant IRF3 protein (60-100 ng; Abnova) along with the same binding buffer used for EMSAs. Samples were incubated at 4 °C for 20 min before they were run on DNA retardation gels at 250 V on ice for 20 min. The samples were then transferred on ice to a nitrocellulose membrane for western blotting (30 V for 1 h). Following transfer, the membrane was blocked with 5% milk in TBST for 1 h with rocking at room temperature before primary antibody was applied (1:1,000 dilution in 5% milk) overnight at 4 °C, with rocking. Antibodies used for WEMSAs included antibodies to CTCF (Cell Signaling Technology, 2899;
